anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE: There is a lack of studies in the literature to evaluate the impact of the specific benefit of the use of neo-adjuvant chemotherapy (NAC) on the negative effect of lymphovascular invasion (LVI) on prognosis. We aimed to evaluate the survival differences of patients according to the presence of LVI with and without administration of NAC before radical cystectomy (RC).
MATERIALS AND METHODS: We retrospectively evaluated data of the patients who underwent RC with pelvic lymphadenectomy and urinary diversion for bladder cancer recorded in the bladder cancer database of the Turkish Uro-oncology Association between 2007 and 2021. Patient demographics, follow-up time and overall survival (OS) were noted.
RESULTS: A total of 633 subjects included in the analyses. Median follow-up time was 24 months (IQR 12-54). Five years OS of the whole cohort was 55.1%. This was 54.7% and 59.9% in NAC- and NAC+ groups (P = 0.683), respectively. It was also 35.7% and 65.7% in LVI+ and LVI- patients (P < 0.0001), respectively. There was a significant difference between LVI+ and LVI- patients (33.2% vs. 68.2%, P < 0.0001) in NAC- group, but similar 5-year OS was found (53.2% vs. 64.5%, P = 0.552) in NAC+ group. In multivariable analyses, female gender, pN stages, presence of variant histology and LVI were significant independent predictive factors for OS in the whole cohort and in the NAC- group. However, gender association, pN stages and LVI lost significance in NAC+ group.
CONCLUSION: Presence of LVI significantly reduced OS, and the NAC treatment improved the negative effects of LVI on OS. Our findings encourage the use of NAC before RC.
Patients presenting with an isolated abnormal head posture, first diagnosed as cervical dystonia, demonstrated in fact, after neurological screening, to be of psychogenic origine. These patients are not candidate for functional surgery and, furthermore, usually refuse psychotherapy leading them to medical nomadism. This study proposes to evaluate the efficacy of an innovative intervention program based on Heart Rate Variability (HRV) biofeedback that promotes self-regulatory skills in dysfunctional movement disorders (DMD) patients in order to improve their condition and symptomatology.

Heart rate is under the control of efferent sympathetic and vagal activities directed to the sinus node, which are modulated by central brain stem (vasomotor and respiratory centers) and peripheral oscillators (oscillation in arterial pressure and respiratory movements). Spectral analysis of HRV is a reliable quantitative method for analyzing the modulatory effects of neural mechanisms on the sinus node. Several biofeedback protocols and assistive electronic technologies, such as proposed by SymbioCenter©, exist to enhance increase HRV and synchronize respiration with the heart rhythm. HRV biofeedback training appears to be an opportunity in the patient's management in order of preventing medical overconsuming. It is offering a safe and non-pharmacological alternative approach managed by a multidisciplinary team in a functional neurosurgery unit. It is expected that developing respiratory coherence in these patients will improve their painful symptomatology.
The zinc finger protein of the cerebellum (ZIC) family comprises five members (ZIC1-5), homologous with the odd-paired (OPA) gene in Drosophila melanogila. These transcription factors contain five Cys2His zinc finger domains, constituting one of the most abundant transcription factor families in human cells. ZIC proteins significantly contribute to transcriptional regulation and chromatin remodeling. As a member of the ZIC family, ZIC5 is essential for animal growth and development. Numerous studies have investigated the connection between ZIC proteins and cancer as well as tumor metastases in recent years. Many studies have found that within tumor tissues, the transcription and translation processes increase the expression of ZIC5 which is linked to tumor aggressiveness. This review aims to provide an objective summary of the impact of ZIC5 on tumor metastasis and consider the potential application of ZIC5 targets in both tumor therapy and the early detection of cancer.
In Part 2, it was planned to enrol up to 10 new patients to participate in 1-day treatment arms in random order (iLet-based Bionic Pancreas using Lilly glucagon and iLet-based Bionic Pancreas using ZP4207 (dasiglucagon) {experimental drug} with insulin lispro) according to pre-generated randomization scheme. However, due to unavailability of the iLet, the sponsor decided to stop the trial upon completion of Part 1. Part 2 of the trial using the iLet was consequently not conducted.
BACKGROUND: Transurethral holmium laser enucleation of the prostate (HoLEP) has a good therapeutic effect on benign prostatic hyperplasia (BPH). The purpose of this study was to investigate the clinical efficacy of HoLEP in the treatment of high-risk elderly patients with BPH and assess its impact on the inflammatory response, vascular endothelial function and quality of life (QoL).
METHODS: Patients at high risk of BPH who were hospitalised in Chengde Central Hospital from February 2021 to December 2022 were retrospectively selected as the study objects, and a total of 100 cases were included. The control group underwent transurethral resection of the prostate, and the observation group underwent HoLEP. Perioperative indexes, urodynamic indexes, QoL 6 months after surgery and incidence of postoperative complications were compared between the two groups. Moreover, serum levels of inflammatory factors and vascular endothelial factors were detected in two groups.
RESULTS: We found no significant difference in general data between the two groups of patients (p > 0.05). The operation time, perioperative bleeding, bladder flushing time and hospitalisation time of the observation group were significantly shorter than those of the control group (p < 0.05). On the 7th day after surgery, the serum levels of tumour necrosis factor alpha, interleukin-1β, interleukin-6, vascular endothelial growth factor, basic fibroblast growth factor and endothelin-1 in the observation group were significantly lower than those in the control group (p < 0.05). Six months after surgery, the maximal urinary flow rate and QoL scores of the patients in the observation group were significantly higher than those of the control group (p < 0.05), and the residual urine volume and International Prostate Symptom Score of observation group were significantly lower than those of the control group (p < 0.05). The incidence of postoperative complications in the observation group was significantly lower than that in the control group (χ2 = 7.440, p = 0.006).
CONCLUSIONS: HoLEP can effectively remove hyperplasia of the prostate and reduce the inflammatory response in the patient's body when treating BPH in high-risk elderly patients. It can also regulate the levels of vascular endothelial factors and effectively improve the patient's QoL.
FIELD: pharmacy. SUBSTANCE: invention relates to oral pharmaceutical composition exhibiting the controlled drug release. Composition has 10-160 mg oxycodone or its salt and provides mean-maximal oxycodone concentration in plasma in vivo up to 240 ng/ml in 2-4.5 h after administration and mean-minimal concentration of oxycodone in plasma in vivo up to 120 ng/ml in 10-14 h after repeated administration each 12 h at stationary condition. New oral pharmaceutical composition is made as a solid medicinal form and has analgetically effective amount of spheroids, sphere-forming agent and film cover regulating oxycodone or oxycodone salt release at the controlled rate. Solid oral medicinal form as a tablet is preferable. New compositions provide the pain relief in 90% patients at significant dose level decrease. EFFECT: enhanced effectiveness of composition. 11 cl, 5 dwg, 18 tbl, 19 ex
1,173,145. Antiviral medicament. J. ASTRUC and A. SAUTAREL. 30 Nov., 1966 [3 Nov., 1965], No. 46662/65. Heading A5B. An antiviral medicament comprises the sterile filtrate from a culture of a new strain of Bacillus macerans, which has been called Petrobacillus avenae 926. A nutrient medium containing bacteriological peptone, glucose, sodium chloride and water, is sterilised, cooled and inoculated. Cultivation is at pH 7.8 and 36 to 38C. and is continued to a germ content of 10<SP>10</SP> germs per ml. 0.4% of formaldehyde solution USP XVI is added and the culture is filtered through a bacteria-proof filter to remove the microbial bodies. The sterile filtrate may be incorporated into medicaments in the form of a solution for injection or oral administration, an ointment, a rectal or vaginal preparation, a nasal or ophthalmic preparation or aerosols. Alternatively, the sterile filtrate may be lyophilised or formed into microcapsules and then formulated into tablets or capsules. The preparations have a non-specific antiviral activity against viruses pathogenic to humans, animals and plants.
One subcutaneous injection of 225IU AFOLIA (follitropin alfa) per day (initial dose) for the first 5 days. From day 6 dose could be adjusted up (to a max of 450IU per day) or down (to a min of 75IU per day) in multiple increments of 37.5IU.
In one of the first papers on the impact of early-life conditions on individuals' health in older age, Barker and Osmond [Lancet, 327, 1077-1081 (1986)] show a strong positive relationship between infant mortality rates in the 1920s and ischemic heart disease in the 1970s. We merge historical data on infant mortality rates to 370,000 individual records in the UK Biobank using information on local area and year of birth. We replicate the association between the early-life infant mortality rate and later-life ischemic heart disease in our sample. We then go "beyond Barker," by showing considerable genetic heterogeneity in this association that is robust to within-area as well as within-family analyses. We find no association between the polygenic index and heart disease in areas with the lowest infant mortality rates, but a strong positive relationship in areas characterized by high infant mortality. These findings suggest that advantageous environments can cushion one's genetic disease risk.
This multi-center, open-label study is designed to evaluate the long-term safety and effectiveness of clobazam as adjunctive therapy in subjects with LGS. Subjects enrolled in Lundbeck LLC (formerly Ovation Pharmaceuticals, Inc.) sponsored studies 13108A/OV1002/NCT00162981 and 13110A/OV1012/NCT00518713 who either completed the study or who prematurely discontinued were offered the opportunity to rollover into this open-label study. Subjects will start at a common dose level of 0.5 mg/kg, not to exceed 40 mg/day, and must maintain the dose level for 48 hours. After 48 hours, investigators will be able to increase, decrease or maintain the subject's dose, up to a maximum target daily dose of 2.0 mg/kg (maximum dose of 80 mg/day). During the treatment period, seizures will be recorded during the week preceding each study visit or 30 days immediately following each study visit (dependent on Amendment approval). The subject or subject's caregiver will record daily counts of seizures, including drop seizures in the subject's seizure diary.
To evaluate the tolerability and ability to achieve target trough L-citrulline levels of 100-150 µM, an additional group of 18 infants (group 3) will be given oral L-citrulline doses at intervals over a total of 72 hours. If the participant is not nipple feeding, the dose will be delivered via the participant's indwelling gavage feeding tube. The dose and interval of L-citrulline will be based on results from the studies that assess pharmacokinetic parameters using a maximum daily dose of 3 g/kg/d. Blood draws for PKs will be done at baseline and prior to last dose of L-citrulline. Urine will be collected to measure nitric oxide metabolites.
BACKGROUND: Parkinson's disease (PD) is a neurodegenerative movement disorder with prodromal and highly prevalent gastrointestinal (GI) symptoms, especially constipation. Although PD models suggest gut-brain axis dysfunction, the mechanistic underpinnings and their correlation with GI symptoms are poorly understood.
AIM: To examine the bidirectional gut-brain axis function in PD and correlate it with constipation severity, PD duration, and severity.
METHODS: Rectal sensory thresholds and afferent cortical evoked potentials (CEP) were assessed using a 4-ring EMG electrode probe. Efferent anal and rectal motor evoked potentials (MEPs) were obtained following transcranial and lumbosacral magnetic stimulation. Bowel symptoms were assessed by prospective stool diary. The CEP and MEP latencies, rectal sensory thresholds, and anorectal sensorimotor data were compared between PD subjects and age-adjusted healthy subjects.
KEY RESULTS: Twenty-five PD subjects with constipation (F/M = 6/19) and 20 healthy subjects (F/M = 14/6) were enrolled. The first and pain sensation thresholds were higher in PD subjects than healthy subjects (p < 0.002) but lost significance after adjustment for age. Age-adjusted rectal CEP and right-sided cortico-anal MEP latencies were prolonged in PD subjects compared to healthy subjects (p < 0.04). Also, half (4 of 8) age-adjusted spino-anal and rectal MEP latencies in PD subjects were significantly longer. In multivariate linear analysis, first rectal sensation and right-sided MEP latencies showed moderate correlation with constipation severity.
CONCLUSIONS & INFERENCES: Parkinson's disease is associated with significant bidirectional gut-brain axis dysfunction as evidenced by prolonged afferent and efferent neuronal signaling. Constipation severity in PD is correlated to abnormal rectal sensation and lateralized disturbance of efferent brain-gut signaling.
FIELD: medicine; pharmaceuticals.SUBSTANCE: pharmaceutical composition for nasal administration comprises a complex of active components based on diphenhydramine hydrochloride, zinc sulfate and a water-soluble vasoconstrictor and a complex of auxiliary components comprising an isotonic agent, pH adjusting agent, a pharmaceutically acceptable gelling agent, a quaternary ammonium compound preservative and distilled water in the amounts indicated in the claims. As a vasoconstrictor, the composition comprises xylometazoline hydrochloride or phenylephrine hydrochloride. As a gelling agent, it contains carboxymethylcellulose or hydroxypropylmethylcellulose. As a preservative, the composition contains benzalkonium chloride or dodecyldimethylbenzylammonium chloride. As an isotonic agent, it contains sodium chloride or sodium hydrogencarbonate. As an agent regulating the pH of the aqueous phase, it contains sodium citrate, citric acid or sodium hydrochloride.EFFECT: composition of the invention is characterized by high therapeutic efficacy and accelerates the epithelialization process of the nasal mucosa.8 cl, 4 ex
The invention discloses space lactobacillus plantarum FH-SS 18-86365L with a liver protection effect and application thereof. The lactobacillus plantarum FH-SS 18-86365L provided by the invention has a preservation number of CGMCC No. 16124. The invention also protects a microbial inoculum taking lactobacillus plantarum SS18-86365L as an active ingredient. The invention also protects the application of the lactobacillus plantarum SS18-86365L or the microbial inoculum in preparing medicaments. The application of the medicine is to treat and/or prevent fatty liver. The medicine is used for treating and/or preventing hyperlipidemia. The medicine is used for protecting liver. The lactobacillus plantarum SS18-86365L provided by the invention has the effects of protecting the liver and inhibiting the formation of fatty liver, and has wide market application prospect.
This study explored the association between experimentally-induced pain sensitivity and µ-opioid receptor (μOR) availability in patients with temporomandibular disorder (TMD) and further investigated any changes in the pain and μOR availability following high-definition transcranial direct current stimulation (HD-tDCS) over the primary motor cortex (M1) with pilot randomized clinical trials. Seven patients with TMD completed either active (n = 3) or sham treatment (n = 4) for 10 daily sessions and underwent positron emission tomography (PET) scans with [11C]carfentanil, a selective μOR agonist, a week before and after treatment. PET imaging consisted of an early resting and late phase with the sustained masseteric pain challenge by computer-controlled injection of 5% hypertonic saline. We also included 12 patients with TMD, obtained from our previous study, for baseline PET analysis. We observed that patients with more sensitivity to pain, indicated by lower infusion rate, had less μOR availability in the right amygdala during the late phase. Moreover, active M1 HD-tDCS, compared to sham, increased μOR availability post-treatment in the thalamus during the early resting phase and the amygdala, hippocampus, and parahippocampal gyrus during the late pain challenge phase. Importantly, increased μOR availability post-treatment in limbic structures including the amygdala and hippocampus was associated with decreased pain sensitivity. The findings underscore the role of the μOR system in pain regulation and the therapeutic potential of HD-tDCS for TMD. Nonetheless, large-scale studies are necessary to establish the clinical significance of these results. TRIAL REGISTRATION: ClinicalTrial.gov (NCT03724032) PERSPECTIVE: This study links pain sensitivity and µ-opioid receptors in patients with TMD. HD-tDCS over M1 improved µOR availability, which was associated with reduced pain sensitivity. Implications for TMD pain management are promising, but larger clinical trials are essential for validation.
Method for eliciting an immune response in a vertebrate subject are provided involving administration of a peptide antigen to the subject in a coordinated vaccination procedure that also involves administration of a non-viral vector that encodes a T cell co-stimulatory molecule. The peptide antigen contains at least one T cell epitope and may include an epitope of a tumor antigen or an antigen of a viral or non-viral pathogen. Epitopes from tumor antigens may represent fragments or partial amino acid sequences of p53, ras, rb, mcc, apc, dcc; nfl; VHL; MEN1, MEN2, MLM, Her-2neu, CEA, PSA; Muc1, Gp100, tyrosinase, or MART1 proteins, and often span a mutation identified in the tumor antigen. Various viral antigens may be selected, for example antigens identified in a human immunodeficiency virus (HIV), hepatitis B virus (HBV), herpes simplex virus (HSV) or human papilloma virus (HPV), for production of peptide antigens corresponding to immunogenic epitopes of the viral antigen. The peptide antigen is administered simultaneously or sequentially with administration of the vector encoding the co-stimulatory molecules. Co-stimulatory molecules useful for coordinate administration with peptide antigens to elicit an enhanced T cell-mediated immune response may be selected from B7-1, B7-2, B7-3, ICAM1, ICAM2, LFA1 or LFA2. The peptide antigen and non-viral vector encoding the T cell co-stimulatory molecule are administered to proximal target sites selected from the same, or closely-adjacent, intradermal, subcutaneous, mucosal or intratumoral sites.
Placebo (lactose) 3 g/day until hospital discharge or 28-days (whichever comes first). Placebo to be provided in powder form and administered via enteral feeding tube whilst in the ICU and orally once able to eat and drink.
Patients receive saracatinib PO on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
A therapeutic agent for the treatment of schizophrenia and other mental illnesses comprising a material obtainable from the septal region only of dead non-human brain (as defined in the Specification), said material being in a condition in which the protein has been broken down and rendered soluble.  In the preferred modification this is accomplished by digestion with a proteolytic enzyme.  The dissected tissues from the septal region of swine, sheep or preferably cattle brains are ground or minced, suspended in a protein non-solvent, such as acetone, ethyl ether, methyl, ethyl or propyl alcohol, and filtered or centrifuged to obtain a filter cake which is washed with protein non-solvent and dried.  The dried solids are then suspended in water and a p  proteolytic enzyme, such as papain, pepsin or preferably trypsin, in amount 5-15% by dry weight of dry filter cake, added.  The alkalinity is adjusted to pH 8 by means of sodium hydroxide, 0.1-2.0% w./v. phenol is added, and the mixture is digested at about 37 DEG  C.  The pH is then adjusted to 7 by means of hydrochloric or sulphuric acid and the digested mixture is boiled. The mixture is then thickened and filtered.  The filtrate is dialysed and the dialysed solution freeze-dried.  The freeze-dried material is dissolved in water.  Other methods of digestion mentioned are digestion by salt solutions or boiling solvents; the active components may be separated by counter-current distribution, ion-exchange chromatography or absorption chromatography.  The agent may be injected, the composition being made isotonic with sodium chloride.
Chimeric proteins for cancer immunotherapy can combine different activities by displaying both agonistic and antagonistic properties on a single molecule. However, those usually exhibit toxicities related to their potency being exerted in the entire organism and not only in tissues relevant for cancer treatment. This may be solved by using appropriate vectorization of the chimeric proteins to the tumour microenvironment, where immune cells interact with tumour cells expressing immunomodulatory molecules. The present invention relates to a nucleic acid encoding a chimeric protein or a chimeric protein having a general structure of: N terminus-(a)-(b)-(c)-C terminus, wherein: (a) is a signaling and/or targeting domain. (b) is a linker (b) is a functional linker and (c) is a signaling and/or targeting domain or N terminus-(c)-(b)-(a)-C terminus, wherein: (c) is a signaling and/or targeting domain. (b) is a linker (b) is a functional linker and (a) is a signaling and/or targeting domain.
Epidemiological data suggest that moderate hyperoxemia may be associated with an improved outcome after traumatic brain injury. In a prospective, randomized investigation of long-term, resuscitated acute subdural hematoma plus hemorrhagic shock (ASDH + HS) in 14 adult, human-sized pigs, targeted hyperoxemia (200 < PaO2 < 250 mmHg vs. normoxemia 80 < PaO2 < 120 mmHg) coincided with improved neurological function. Since brain perfusion, oxygenation and metabolism did not differ, this post hoc study analyzed the available material for the effects of targeted hyperoxemia on cerebral tissue markers of oxidative/nitrosative stress (nitrotyrosine expression), blood-brain barrier integrity (extravascular albumin accumulation) and fluid homeostasis (oxytocin, its receptor and the H2S-producing enzymes cystathionine-β-synthase and cystathionine-γ-lyase). After 2 h of ASDH + HS (0.1 mL/kgBW autologous blood injected into the subdural space and passive removal of 30% of the blood volume), animals were resuscitated for up to 53 h by re-transfusion of shed blood, noradrenaline infusion to maintain cerebral perfusion pressure at baseline levels and hyper-/normoxemia during the first 24 h. Immediate postmortem, bi-hemispheric (i.e., blood-injected and contra-lateral) prefrontal cortex specimens from the base of the sulci underwent immunohistochemistry (% positive tissue staining) analysis of oxidative/nitrosative stress, blood-brain barrier integrity and fluid homeostasis. None of these tissue markers explained any differences in hyperoxemia-related neurological function. Likewise, hyperoxemia exerted no deleterious effects.
Healthy individuals aged between 18 and 38 years. The dielectric constant will be evaluated with a depth measurement of 2.5 mm, elasticity and infrared thermography in the region of the systemic acupuncture points.